Dimensional Fund Advisors LP Has $42.87 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Dimensional Fund Advisors LP increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 52.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,680,535 shares of the biopharmaceutical company’s stock after acquiring an additional 580,787 shares during the quarter. Dimensional Fund Advisors LP owned 0.29% of Royalty Pharma worth $42,866,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Canada Pension Plan Investment Board grew its position in Royalty Pharma by 5.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 805,615 shares of the biopharmaceutical company’s stock worth $20,551,000 after purchasing an additional 39,070 shares in the last quarter. Jump Financial LLC acquired a new position in Royalty Pharma during the fourth quarter valued at $2,088,000. Bridgewater Associates LP purchased a new stake in Royalty Pharma in the 4th quarter worth about $1,261,000. Portolan Capital Management LLC boosted its position in Royalty Pharma by 101.9% during the 4th quarter. Portolan Capital Management LLC now owns 344,185 shares of the biopharmaceutical company’s stock worth $8,780,000 after acquiring an additional 173,721 shares during the period. Finally, Walleye Capital LLC purchased a new position in Royalty Pharma during the 4th quarter valued at about $641,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 1.3 %

Shares of NASDAQ RPRX opened at $32.89 on Friday. The business has a 50 day simple moving average of $32.46 and a 200 day simple moving average of $29.60. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a market cap of $18.96 billion, a price-to-earnings ratio of 22.68, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.68%. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Analyst Ratings Changes

Separately, Citigroup restated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Royalty Pharma has a consensus rating of “Buy” and an average target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.